The protein inhibitors market consists of sales of protein inhibitors by entities (organizations, sole traders, and partnerships) that are engaged in the manufacturing of protein inhibitors. Protein synthesis inhibitors stop the development of cells by disrupting the process leading to the generation of new proteins. Protein inhibitors is a pharmaceutical drug that acts on the proteins (special target) in the body and finds applications in the treatment of various diseases such as cancer, autoimmune diseases, infectious diseases, and others.
The global protein inhibitors market is expected to decline from $59.66 billion in 2019 to $56.97 billion in 2020 at a compound annual growth rate (CAGR) of -4.5%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $75.37 billion in 2023 at a CAGR of 9.78%.